PledPharma AB. (11/6/20). "Press Release: Henrik Krook Appointed VP Commercial Operations at PledPharma". Stockholm.

	Organisation	PledPharma AB (STO: PLED)
	Today	Egetis Therapeutics AB (STO: EGTX)
	Group	Egetis Therapeutics (Group)
	Organisation 2	Affibody Medical AB
	Product	Aladote®
	Product 2	Emcitate®
	Index term 2	Rare Thyroid Therapeutics–PledPharma: investment, 202010–202011 acquisition of RTT for SEK60m + 63.77m new shares + milestones
	Person	Krook, Henrik (PledPharma 202012– VP Commercial Operations before Affibody + Alexion + Novartis + Roche)
	Person 2	Westerholm, Nicklas (PledPharma 202011 CEO)

PledPharma AB (STO: PLED) today announced that Henrik Krook takes on the position as Vice President Commercial Operations at PledPharma. The appointment is complementing PledPharma’s acquisition of Rare Thyroid Therapeutics (RTT), creating a new focused orphan drug development company with a commercial capability. Henrik will join the company in December.

Henrik has a broad experience from over 15 years in commercial leadership settings, including both big pharma and biotechs. He has direct experience in general management, business development, market access, marketing, sales, clinical trials and strategy formulation, including the orphan drug segment, with a track record of developing companies, organizations and assets to ensure continuous value creation. He has previously held different senior corporate and commercial advisory roles for biotech companies such as Affibody and senior managerial positions at e.g. Alexion, Novartis and Roche.

He has a PhD in clinical immunology from Uppsala University Hospital and an Executive MBA from Stockholm School of Economics.

“We are very happy to recruit Henrik. With his extensive experience from preparing and executing launches of specialty care drugs, including several in rare diseases, he will be an important addition when we now take important steps towards creating a orphan drug company with products on the market where there is a great unmet medical need. With Henrik on board, we are starting to build the capability to be able to launch our lead candidates Aladote® and Emcitate® in EU and US through a niche commercial organization in approximately three years,” said Nicklas Westerholm, CEO, PledPharma.

For further information, please contact:

Nicklas Westerholm, Verkställande direktör
Tel. 073 354 20 62
nicklas.westerholm@pledpharma.se

About PledPharma

PledPharma is an innovative, unique and integrated pharmaceutical drug development company, focusing on improving treatments for diseases with substantial unmet medical need. The drug candidate Aladote® is a first in class drug candidate developed to reduce the risk of acute liver injury associated with paracetamol poisoning. A proof of principle study has been successfully completed and the design of the upcoming pivotal Phase IIb/III study for Aladote has been finalized after completed interactions with FDA, EMA and MHRA. Aladote® has been granted Orphan Drug Designation in the US. The Phase III POLAR program for the drug candidate PledOx® was prematurely stopped in Q2 2020. Results from POLAR program will determine if further development of PledOx is warranted via strategic partnerships and is expected to be announced in Q4 2020. Through the acquisition of Rare Thyroid Therapeutics (RTT), the clinical portfolio also includes Emcitate®, for the treatment of MCT8 deficiency, a rare disease with high unmet medical need and no available treatment. A pivotal Phase IIb/III early intervention study is planned to start in Q4 2020. Emcitate has been granted Orphan Drug Designation in the US and EU.

PledPharma (STO: PLED) is listed on the Nasdaq Stockholm main market since October 31, 2019. For more information, see http://www.pledpharma.com/

Record changed: 2023-06-05